Physician profile
Meredith S Reimer
NPI 1629273909
$12,398.09
in general payments reported to CMS, 2019-2025
38 companies · $1,543 in 2025
The $1,543 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $985 · 2020: $1,342 · 2021: $1,527 · 2022: $1,369 · 2023: $3,082 · 2024: $2,549 · 2025: $1,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,916 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,915.73 |
| Education | $258.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,576.61 | 2019-2025 | |
| Janssen Biotech, INC. | $1,368.25 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $1,262.74 | 2019-2025 | Absorica Ld, Winlevi, Blu-U |
| Galderma Laboratories, L.P. | $851.57 | 2019-2025 | Aklief, Nemluvio, Dysport |
| E.R. Squibb & Sons, L.L.C. | $640.31 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $626.82 | 2020-2025 | |
| Amgen INC. | $591.53 | 2020-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $582.54 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $571.55 | 2021-2025 | Dupixent, Libtayo |
| Journey Medical Corporation | $559.98 | 2019-2024 | |
| Lilly USA, LLC | $549.69 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $470.48 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $378.51 | 2022-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $365.00 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $273.61 | 2019-2025 | Jublia, Arazlo, Cabtreo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $256.00 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $220.07 | 2019-2024 | |
| Incyte Corporation | $179.98 | 2021-2024 | Opzelura |
| Biofrontera INC. | $134.15 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $126.69 | 2025 | Vtama |
| Almirall LLC | $120.31 | 2019-2023 | Seysara |
| Celgene Corporation | $116.40 | 2019 | |
| Vyne Pharmaceuticals INC. | $94.03 | 2020-2021 | |
| Strata Skin Sciences, INC. | $70.41 | 2024-2025 | Xtrac |
| Dermira, INC. | $62.58 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $45.13 | 2024 | Zoryve |
| Allergan, INC. | $42.68 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.44 | 2022-2025 | Spevigo |
| Verrica Pharmaceuticals INC. | $36.36 | 2023-2024 | Ycanth |
| Prugen, INC. Pharmaceuticals | $35.68 | 2019-2020 | |
| Epi Health, LLC | $32.32 | 2022 | |
| Taro Pharmaceuticals USA, INC. | $19.25 | 2019 | |
| Lnhc, INC | $18.00 | 2025 | Zelsuvmi |
| Botanix Sb INC | $17.42 | 2025 | Sofdra |
| Conmed Corporation | $16.50 | 2023 | Airseal |
| Stemline Therapeutics INC. | $15.79 | 2022 | |
| Promius Pharma LLC | $15.06 | 2019 | |
| Janssen Scientific Affairs, LLC | $14.65 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Reimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.